In the latest session, Royalty Pharma plc (NASDAQ: RPRX) closed at $29.93 down -1.35% from its previous closing price of $30.34. In other words, the price has decreased by -$0.41 from its previous closing price. On the day, 2680910 shares were traded.
Ratios:
For a deeper understanding of Royalty Pharma plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.41. For the most recent quarter (mrq), Quick Ratio is recorded 7.90 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.94.
On May 13, 2022, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $53.
On April 27, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $56.Goldman initiated its Buy rating on April 27, 2022, with a $56 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 04 when RIGGS RORY B sold 35,702 shares for $27.55 per share. The transaction valued at 983,504 led to the insider holds 20,099 shares of the business.
RIGGS RORY B sold 199,098 shares of RPRX for $5,532,276 on Jan 03. The Director now owns 55,801 shares after completing the transaction at $27.79 per share. On Jan 02, another insider, RIGGS RORY B, who serves as the Director of the company, sold 235,200 shares for $28.52 each. As a result, the insider received 6,707,081 and left with 254,899 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 13.37B and an Enterprise Value of 18.27B. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.80, and their Forward P/E ratio for the next fiscal year is 7.38. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.68 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 7.76 whereas that against EBITDA is 9.68.
Stock Price History:
Over the past 52 weeks, RPRX has reached a high of $38.19, while it has fallen to a 52-week low of $25.92. The 50-Day Moving Average of the stock is 28.94, while the 200-Day Moving Average is calculated to be 29.31.
Shares Statistics:
For the past three months, RPRX has traded an average of 2.91M shares per day and 3.61M over the past ten days. A total of 446.69M shares are outstanding, with a floating share count of 378.88M. Insiders hold about 15.18% of the company’s shares, while institutions hold 68.61% stake in the company. Shares short for RPRX as of Feb 15, 2024 were 11.5M with a Short Ratio of 3.95, compared to 10.19M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.57% and a Short% of Float of 2.69%.
Dividends & Splits
According to the company, the forward annual dividend rate for RPRX is 0.81, from 0.80 in the trailing year. Against a Trailing Annual Dividend Yield of 2.64%, it implies a Forward Annual Dividend Yield of 2.81%.
Earnings Estimates
There are 4 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.88 for the current quarter, with a high estimate of $0.99 and a low estimate of $0.81, while EPS last year was $1.6. The consensus estimate for the next quarter is $0.88, with high estimates of $0.97 and low estimates of $0.79.
Analysts are recommending an EPS of between $4.02 and $2.97 for the fiscal current year, implying an average EPS of $3.65. EPS for the following year is $3.98, with 6 analysts recommending between $4.71 and $2.8.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $643.61M this quarter.It ranges from a high estimate of $715.88M to a low estimate of $533.94M. As of the current estimate, Royalty Pharma plc’s year-ago sales were $852.9M, an estimated decrease of -24.50% from the year-ago figure.
A total of 5 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $2.79B, while the lowest revenue estimate was $2.39B, resulting in an average revenue estimate of $2.62B. In the same quarter a year ago, actual revenue was $2.35B, up 11.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.87B in the next fiscal year. The high estimate is $3.23B and the low estimate is $2.57B. The average revenue growth estimate for next year is up 9.60% from the average revenue estimate for this year.
